
BLCO Stock Forecast & Price Target
BLCO Analyst Ratings
Bulls say
Bausch & Lomb has demonstrated robust growth across its segments, with contact lens market share increasing by 40 basis points year-over-year to 10% and surgical revenues reaching $231 million, representing a 13% increase year-over-year. The ophthalmic pharmaceuticals segment also showed positive momentum, with revenues of $326 million growing by approximately 6% year-over-year, in spite of foreign exchange headwinds, while consumer segment revenues climbed to $476 million, up 8% year-over-year, exceeding analyst expectations. Additionally, the notable strength in premium intraocular lenses, which saw a 67% year-over-year increase, highlights Bausch & Lomb’s diverse and expanding product portfolio, further reinforcing a favorable outlook for the company.
Bears say
Bausch & Lomb is facing a negative outlook primarily due to projected flat to low-single digit revenue growth, which is expected to impede operating margin improvement and earnings per share (EPS) growth. The company is contending with multiple operational risks, including competitive pressures from lower-cost online contact lens providers, potential disruptions from ongoing geopolitical conflicts, and challenges in executing commercial launches. Additionally, revisions to EPS forecasts indicate a decline, with estimates for 2025 and 2026 reduced significantly, highlighting concerns over its market positioning amid lower margins in certain segments and high leverage.
This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.
BLCO Analyst Forecast & Price Prediction
Start investing in BLCO
Order type
Buy in
Order amount
Est. shares
0 shares